ArticleEpidemiology and infection2017
Seroprevalence of cytomegalovirus infection in France in 2010.
Article in Epidemiology and infection, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development.BMC public health · 2022Pooled it
- Seroprevalence and risk factors of cytomegalovirus infection in pregnant women in Lebanon: A retrospective study conducted at Hôtel-Dieu de France.IJID regions · 2026Article
- Cytomegalovirus seroprevalence and seroconversion in the Irish blood donor population.Epidemiology and infection · 2026Article
- Review
- Prevalence of Cytomegalovirus Antibodies in Croatian Childbearing-Aged and Pregnant Women: A Ten-Year Retrospective Study (2015-2024).Pathogens (Basel, Switzerland) · 2025Article
- CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.Nature medicine · 2025Article
- Cytomegalovirus Infection Screening in Pregnant Women from Northwest Romania: Results of a 15-Year Follow-Up Program.Microorganisms · 2025Article
- Cytomegalovirus and Epstein-Barr virus infections among Jordanians: seroprevalence and associated factors.BMC infectious diseases · 2025Article
- Frequency of CMV testing during pregnancy-a retrospective study.Archives of gynecology and obstetrics · 2025Article
- Advancements in Cytomegalovirus Management Among Solid Organ Transplant Recipients: Insights From the ESOT CMV Workshop 2023.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- The Cost-effectiveness of Valganciclovir Prophylaxis Versus Preemptive Therapy in CMV R+ Kidney Transplant Recipients Over the First Year Posttransplantation.Transplantation direct · 2024Article
- Screening for TORCH Antibodies in Croatian Childbearing-Aged Women, 2014-2023.Antibodies (Basel, Switzerland) · 2024Article
- Seroprevalence of Anti-Cytomegalovirus Antibodies in Pregnant Women from South-West Romania.Microorganisms · 2024Article
- Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8Science advances · 2023Article
- Seroprevalence of Infections with TORCH Agents in Romania: A Systematic Review.Microorganisms · 2023Review
- [Effect of breastfeeding on immune function in infants with human cytomegalovirus infection].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2023Article
- Challenges, Recent Advances and Perspectives in the Treatment of Human Cytomegalovirus Infections.Tropical medicine and infectious disease · 2022Review
- The Association of Cytomegalovirus IgM and Allostatic Load.Diseases (Basel, Switzerland) · 2022Article
- CMV Infection and CMV-Specific Immune Reconstitution Following Haploidentical Stem Cell Transplantation: An Update.Frontiers in immunology · 2021Review
- Prevalence and Recurrence Rates of Cytomegalovirus Infection Among Patients With Hematological Diseases in the Western Brazilian Amazon: A Cross-Sectional Study.Frontiers in public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytomegalovirus (CMV) infection remains the leading cause of congenital virus infection in developed countries. Measuring the national prevalence of this infection, especially among women of childbearing age, is of great value to estimate the risk of congenital CMV infection, as well as to identify risk groups that should be targeted for behavioural interventions and/or vaccination once a CMV vaccine finally becomes available. In order to fulfil these objectives, a seroprevalence survey was conducted in 2010, using a nationally representative, population-based sample of 2536 people aged between 15 and 49 years, living in metropolitan France and attending private microbiological laboratories for blood testing. All blood samples were analysed in the same laboratory and screened for CMV-specific IgG using an enzyme-linked immunoassay technique (Elisa PKS Medac Enzyme immunoassay). The overall point estimate of CMV infection seroprevalence for individuals aged 15-49 years was 41.9%. The estimates were higher in women than in men (respectively 45.6% and 39.3%), and people born in a non-Western country were more likely to be CMV seropositive than those born in France or in another Western country (93.7% vs. 37.7%). Our results showed that a substantial percentage of women of childbearing age in France are CMV seronegative and therefore at risk of primary CMV infection during pregnancy. Educational measures and future vaccine are key issues to prevent infection in pregnant women and congenital CMV disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.